Loxo Oncology Inc. (LOXO) Soared To A New High On Study Results

Loxo Oncology Inc. (LOXO) announced Monday morning that its cancer drug larotrectinib demonstrated a 76 percent confirmed objective response rate across tumor types.

from RTT - Before the Bell http://ift.tt/2rHweDO
via IFTTT